Skip to the main content

Euclidean Capital

New York Founded 2009 Website
Cheque Size$1M to $50M
Stages5
Industries15
Markets20
Stated Portfolio15
Operating Since2009 (17y)

About Euclidean Capital

Euclidean Capital is a private investment firm managing the personal wealth of James Simons, founder of Renaissance Technologies. The firm oversees a diversified global investment portfolio across public and private markets, supporting long-term capital preservation, growth, and philanthropic initiatives. Euclidean Capital employs a disciplined investment approach and rigorous risk management, allocating capital to various asset classes, including private equity, venture capital, public equity, alternative investments, and philanthropic endeavors on behalf of the Simons family. The firm's investment strategy encompasses multiple stages, such as early stage, growth, late stage, pre-IPO, and buyout, with a geographical focus spanning the United States, Europe, Asia, Africa, South America, Australia, Canada, Mexico, India, China, Japan, South Korea, Brazil, Argentina, Chile, Colombia, Peru, Egypt, South Africa, and Nigeria. Euclidean Capital's portfolio includes investments in diverse industries, including technology, healthcare, biotechnology, consumer goods, financial services, energy, real estate, media, telecommunications, transportation, industrial goods, materials, utilities, consumer services, and retail. The firm typically invests between $1 million and $50 million in each opportunity, aiming to generate substantial returns while supporting the growth and development of its portfolio companies. Euclidean Capital's commitment to long-term value creation and its diversified investment approach reflect its dedication to preserving and growing the Simons family's wealth across various sectors and geographies.

Geographical Focus

African markets3

Other stated markets17

United StatesCanadaJapanAustraliaEuropeAsiaChinaIndiaBrazilMexicoSouth KoreaChileArgentinaColombiaPeruAfricaSouth America

Requirements

Strong management teams, Innovative business models, Scalable growth potential, Competitive market positioning, Clear exit strategies

Stated Portfolio15

23andMe
Surrozen
Alector
Savvy Wealth
April
Neurona Therapeutics
Judo Bio
Leal Therapeutics
Nura Bio
Circle Pharma
PMV Pharmaceuticals
Peltarion
Actio Biosciences
Zeitview
Neo Asset Management

As reported by the investor. We hold no profile for these companies, so they are printed as stated rather than linked.

Is this you?

Claim this investor profile to manage your firm's information.

Claim this profile
Report an error

Contact

Profile

TypeFamily Office
CityNew York
Founded2009
Minimum Cheque$1M
Maximum Cheque$50M